GoodRx Projects 2026 Revenue and EBITDA Decline Amidst Core Business Challenges

summarizeSummary

GoodRx's latest earnings report reveals a mixed picture, with 2025 financial results meeting prior expectations but forward guidance for 2026 indicating a significant slowdown. The company anticipates a 2-6% revenue decline and a substantial drop in Adjusted EBITDA for the upcoming year. This negative outlook is compounded by a continued decrease in Monthly Active Consumers and subscription plans, signaling ongoing challenges in its core prescription transaction and subscription segments. While the Pharma Direct segment showed strong growth, it was not enough to offset the broader declines. Investors should monitor the company's ability to stabilize its core business and execute on its strategy to return to overall growth beyond 2026, especially given the stock is trading near 52-week lows.

check_boxKey Events

• Full Year 2025 Results In-Line

  GoodRx reported full-year 2025 revenue of $796.9 million and Adjusted EBITDA of $270.5 million, both aligning with previous guidance. Net income increased to $30.4 million.

• Weak 2026 Guidance Issued

  The company projected full-year 2026 revenue of $750-$780 million, representing a 2-6% decline from 2025, and Adjusted EBITDA of over $230 million, indicating a significant decrease from the prior year.

• Core Metrics Continue to Decline

  Monthly Active Consumers decreased to 5.3 million by year-end 2025, and subscription plans also saw a slight decline, highlighting ongoing challenges in key operating segments.

• Pharma Direct Segment Shows Strong Growth

  Pharma Direct revenue increased 41% year-over-year to $151.4 million in 2025, with the company emphasizing it as a key future growth driver.

auto_awesomeAnalysis

GoodRx's latest earnings report reveals a mixed picture, with 2025 financial results meeting prior expectations but forward guidance for 2026 indicating a significant slowdown. The company anticipates a 2-6% revenue decline and a substantial drop in Adjusted EBITDA for the upcoming year. This negative outlook is compounded by a continued decrease in Monthly Active Consumers and subscription plans, signaling ongoing challenges in its core prescription transaction and subscription segments. While the Pharma Direct segment showed strong growth, it was not enough to offset the broader declines. Investors should monitor the company's ability to stabilize its core business and execute on its strategy to return to overall growth beyond 2026, especially given the stock is trading near 52-week lows.